When Your Partner Goes Broke, You Take the Keys Back

S-oxprenolol is one of two assets in Actimed's cachexia toolbox. The company's lead program is actually a related compound called S-pindolol benzoate (ACM-001), which it describes as a first-in-class "anabolic/catabolic transforming agent," or ACTA.

In plain English, this drug tries to flip a biological switch. Cancer cachexia causes the body to break down muscle (that's catabolism). S-pindolol works on multiple targets simultaneously: it blocks the muscle breakdown, stimulates muscle building through partial activation of beta-2 receptors, and even improves appetite and fatigue through activity on serotonin pathways. Think of it like a three-pronged counterattack against wasting.

Actimed already has Phase 2a proof-of-concept data from a study called ACT-ONE, and it has moved into an FDA-cleared Phase 2b/3 program called IMPACT, targeting cachexia in colorectal cancer and non-small cell lung cancer patients. Getting S-oxprenolol back gives the company a broader portfolio to work with across indications, including the ALS-related muscle wasting it's been focused on all along.

A $2.5 Billion Problem Nobody Has Solved

Cachexia is one of those conditions that sounds obscure until you realize how devastating it is. Up to 80% of advanced cancer patients experience it, and it directly contributes to death in a significant number of cases. The current treatment options are, frankly, terrible. Doctors prescribe appetite stimulants like megestrol acetate, corticosteroids, and TNF inhibitors. These provide, at best, modest symptom relief. None of them actually reverse muscle loss.

The global cachexia treatment market sits at roughly $2.5 to $2.9 billion in 2026, with projections pushing it toward $3.1 to $3.9 billion by the early 2030s. Growth is steady but not explosive; forecasts hover in the mid-single digits, around 4% to 6% annually depending on the scope.

What makes this market interesting isn't its size. It's the vacuum. There is no approved therapy that truly addresses the underlying biology of muscle wasting. Whoever cracks that code first will own an enormous unmet need.

The Competition Is Real (and Well-Funded)

Actimed isn't the only company chasing this prize. Pfizer has ponsegromab, which has generated significant buzz. Helsinn and Ono Pharmaceutical are pushing anamorelin (branded as ADLUMIZ). Endevica Bio has a compound called TCMCB07 in the pipeline. And AVEO Oncology is working on AV-380.

These are serious players with serious resources. Actimed is a small, private biotech going up against pharma giants. Normally that's a David-and-Goliath story with predictable results. But there's a twist: Actimed now has something those competitors might want. An unencumbered global asset with clinical data and no messy licensing strings attached.

That makes Actimed either a future standalone success story or a very attractive acquisition target. Either way, regaining full rights was probably the smartest move available.

The Real Calculus

Trade coverage has been cautiously optimistic. The consensus view is that losing access to $123.5 million in potential milestones stings on paper, but those milestones were always speculative; they depended on Faraday actually developing the drug, which clearly wasn't going to happen. Analysts note that the "unencumbered global package" Actimed now holds could be more attractive to future partners or buyers than a split-rights arrangement ever was.

The risk is obvious, though. S-oxprenolol hasn't entered clinical development yet. The value Actimed reclaimed is almost entirely prospective. It's a bet on their own ability to fund, develop, and either commercialize or re-partner the asset on better terms.

The Bottom Line

Sometimes the best deal is the one that falls apart. Actimed handed off a promising drug to a partner that imploded. Now it has the whole thing back, no strings attached, in a market desperate for something that actually works.

The $123.5 million deal looked great on a press release in 2021. But a clean slate in 2026, with full control and a growing pipeline, might be worth a lot more. Actimed just needs to prove it can go the distance alone, or find a partner that won't run out of gas halfway there.

Biotech's IPO Window Just Cracked Wide Open

BlossomHill Therapeutics just pulled off a $150 million upsized IPO in the busiest week for biotech listings all year. With 2026 already blowing past 2025's full-year IPO numbers, the biotech market's comeback is looking very real.